BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940-987. [PMID: 16530532 DOI: 10.1053/j.gastro.2006.01.048] [Cited by in Crossref: 328] [Cited by in F6Publishing: 303] [Article Influence: 20.5] [Reference Citation Analysis]
Number Citing Articles
1 Weaver KN, Long MD. Preventive Medicine in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2019;17:824-8. [PMID: 30529728 DOI: 10.1016/j.cgh.2018.11.054] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Bossa F, Colombo E, Andriulli A, Annese V. Treatment of steroid-naive ulcerative colitis. Expert Opinion on Pharmacotherapy 2009;10:1449-60. [DOI: 10.1517/14656560902973728] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
3 Gisbert JP, González-Lama Y, Maté J. Systematic review: Infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther. 2007;25:19-37. [PMID: 17229218 DOI: 10.1111/j.1365-2036.2006.03131.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 79] [Article Influence: 6.2] [Reference Citation Analysis]
4 López-Martín C, Chaparro M, Espinosa L, Bejerano A, Maté J, Gisbert JP. Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease. Gastroenterol Hepatol. 2011;34:385-392. [PMID: 21616565 DOI: 10.1016/j.gastrohep.2011.03.023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
5 Afif W, Loftus EV. Safety profile of IBD therapeutics: infectious risks. Med Clin North Am. 2010;94:115-133. [PMID: 19944801 DOI: 10.1016/j.mcna.2009.08.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
6 Dorn SD. Mid-level providers in gastroenterology. Am J Gastroenterol 2010;105:246-51. [PMID: 20139869 DOI: 10.1038/ajg.2009.275] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
7 Wang HH, He Y, Wang HX, Liao CL, Peng Y, Tao LJ, Zhang W, Yang HX. Comparison of TPMT and NUDT15 polymorphisms in Chinese patients with inflammatory bowel disease. World J Gastroenterol 2018; 24(8): 941-948 [PMID: 29491687 DOI: 10.3748/wjg.v24.i8.941] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
8 Gajendran M, Loganathan P, Catinella AP, Hashash JG. A comprehensive review and update on Crohn's disease. Dis Mon. 2018;64:20-57. [PMID: 28826742 DOI: 10.1016/j.disamonth.2017.07.001] [Cited by in Crossref: 108] [Cited by in F6Publishing: 88] [Article Influence: 21.6] [Reference Citation Analysis]
9 Gisbert JP, Gomollón F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol. 2008;103:1783-1800. [PMID: 18557712 DOI: 10.1111/j.1572-0241.2008.01848.x] [Cited by in Crossref: 168] [Cited by in F6Publishing: 146] [Article Influence: 12.0] [Reference Citation Analysis]
10 Oliva-hemker MM, Abadom V, Cuffari C, Thompson RE. Nonadherence With Thiopurine Immunomodulator and Mesalamine Medications in Children with Crohn Disease. Journal of Pediatric Gastroenterology & Nutrition 2007;44:180-4. [DOI: 10.1097/mpg.0b013e31802b320e] [Cited by in Crossref: 43] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
11 Mayer L, Sandborn WJ, Stepanov Y, Geboes K, Hardi R, Yellin M, Tao X, Xu LA, Salter-Cid L, Gujrathi S. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014;63:442-450. [PMID: 23461895 DOI: 10.1136/gutjnl-2012-303424] [Cited by in Crossref: 95] [Cited by in F6Publishing: 83] [Article Influence: 10.6] [Reference Citation Analysis]
12 Rubin DT, Patel H, Shi S, Mody R. Assessment of corticosteroid-related quality of care measures for ulcerative colitis and Crohn’s disease in the United States: a claims data analysis. Current Medical Research and Opinion 2017;33:529-36. [DOI: 10.1080/03007995.2016.1267616] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
13 Zezos P, Zittan E, Islam S, Hudson J, Ben-Bassat O, Nazarian A, Steinhart HA, Silverberg MS, Atri M. Associations between quantitative evaluation of bowel wall microvascular flow by contrast-enhanced ultrasound and indices of disease activity in Crohn's disease patients using both bolus and infusion techniques. J Clin Ultrasound 2019;47:453-60. [PMID: 31343081 DOI: 10.1002/jcu.22763] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Nguyen T, Daubard M, Le Gall C, Larger M, Lachaux A, Boulieu R. Monitoring of Azathioprine Metabolites in Pediatric Patients With Autoimmune Hepatitis. Therapeutic Drug Monitoring 2010;32:433-7. [DOI: 10.1097/ftd.0b013e3181dbd712] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
15 Nanda K, Moss AC. Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine. Clin Pharmacol. 2012;4:41-50. [PMID: 22888278 DOI: 10.2147/CPAA.S26556] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
16 Manceau H, Chicha-Cattoir V, Puy H, Peoc'h K. Fecal calprotectin in inflammatory bowel diseases: update and perspectives. Clin Chem Lab Med. 2017;55:474-483. [PMID: 27658156 DOI: 10.1515/cclm-2016-0522] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 7.8] [Reference Citation Analysis]
17 Tanida S, Ozeki K, Mizoshita T, Tsukamoto H, Katano T, Kataoka H, Kamiya T, Joh T. Managing refractory Crohn's disease: challenges and solutions. Clin Exp Gastroenterol 2015;8:131-40. [PMID: 25914555 DOI: 10.2147/CEG.S61868] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
18 Saibeni S, Virgilio T, D’Incà R, Spina L, Bortoli A, Paccagnella M, Peli M, Sablich R, Meucci G, Colombo E. The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice. Dig Liver Dis. 2008;40:814-820. [PMID: 18479986 DOI: 10.1016/j.dld.2008.03.016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
19 Roblin X, Williet N, Peyrin-Biroulet L. Thiopurine Metabolism in the Era of Combotherapy. Inflamm Bowel Dis 2016;22:1496-501. [PMID: 26978723 DOI: 10.1097/MIB.0000000000000737] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
20 Ricart E, García-Bosch O, Ordás I, Panés J. Are we giving biologics too late? The case for early versus late use. World J Gastroenterol 2008; 14(36): 5523-5527 [PMID: 18810770 DOI: 10.3748/wjg.14.5523] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
21 Benkov K, Lu Y, Patel A, Rahhal R, Russell G, Teitelbaum J. Role of Thiopurine Metabolite Testing and Thiopurine Methyltransferase Determination in Pediatric IBD. Journal of Pediatric Gastroenterology & Nutrition 2013;56:333-40. [DOI: 10.1097/mpg.0b013e3182844705] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
22 Thia KT, Li M, Ling KL, Kong SC, Ooi CJ. Azathioprine is effective in corticosteroid-dependent Asian inflammatory bowel disease patients. Inflamm Bowel Dis. 2011;17:809-815. [PMID: 20645318 DOI: 10.1002/ibd.21382] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
23 Nakase H. Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease. Gut Liver 2020;14:7-19. [PMID: 30919602 DOI: 10.5009/gnl18203] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Cross RK, Cheevers N, Finkelstein J. Home telemanagement for patients with ulcerative colitis (UC HAT). Dig Dis Sci. 2009;54:2463-2472. [PMID: 19104937 DOI: 10.1007/s10620-008-0640-0] [Cited by in Crossref: 37] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
25 Choshen S, Finnamore H, Auth MK, Bdolah-abram T, Shteyer E, Mack D, Hyams J, Leleiko N, Griffiths A, Turner D. Corticosteroid Dosing in Pediatric Acute Severe Ulcerative Colitis: A Propensity Score Analysis. Journal of Pediatric Gastroenterology & Nutrition 2016;63:58-64. [DOI: 10.1097/mpg.0000000000001079] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
26 Abraham BP, Ahmed T, Ali T. Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches. In: Greenwood-van Meerveld B, editor. Gastrointestinal Pharmacology. Cham: Springer International Publishing; 2017. pp. 115-46. [DOI: 10.1007/164_2016_122] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
27 Alhagamhmad MH, Day AS, Lemberg DA, Leach ST. An update of the role of nutritional therapy in the management of Crohn’s disease. J Gastroenterol. 2012;47:872-882. [PMID: 22699323 DOI: 10.1007/s00535-012-0617-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
28 Raj LS, Hawthorne AB. Optimising use of thiopurines in inflammatory bowel disease. Frontline Gastroenterol 2010;1:44-51. [PMID: 28839543 DOI: 10.1136/fg.2009.000174] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
29 Moscandrew M, Mahadevan U, Kane S. General health maintenance in IBD. Inflamm Bowel Dis. 2009;15:1399-1409. [PMID: 19591135 DOI: 10.1002/ibd.20944] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
30 van der Have M, Belderbos TD, Fidder HH, Leenders M, Dijkstra G, Peters CP, Eshuis EJ, Ponsioen CY, Siersema PD, van Oijen MG, Oldenburg B;  Dutch Initiative on Crohn and Colitis (ICC). Screening prior to biological therapy in Crohn's disease: adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study. Dig Liver Dis. 2014;46:881-886. [PMID: 25081843 DOI: 10.1016/j.dld.2014.07.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
31 Cottone M, Criscuoli V. Infliximab to treat Crohn's disease: an update. Clin Exp Gastroenterol 2011;4:227-38. [PMID: 22016584 DOI: 10.2147/CEG.S6440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
32 Rudolph SJ, Weinberg DI, Mccabe RP. Long-Term Durability of Crohn’s Disease Treatment with Infliximab. Dig Dis Sci 2008;53:1033-41. [DOI: 10.1007/s10620-007-9969-z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
33 Sood R, Ansari S, Clark T, Hamlin PJ, Ford AC. Long-term efficacy and safety of azathioprine in ulcerative colitis. J Crohns Colitis 2015;9:191-7. [PMID: 25518053 DOI: 10.1093/ecco-jcc/jju010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
34 Wang Y, Makadia R, Knoll C, Hardin J, Voss EA, Fife D, Davis K, Sloan S. Understanding patient journey in ulcerative colitis prior to biologic initiation: a 5-year exploration. BMC Gastroenterol 2021;21:121. [PMID: 33731009 DOI: 10.1186/s12876-021-01708-6] [Reference Citation Analysis]
35 Badina L, Taddio A, Ventura A. Early combined immunosuppression in Crohn's disease. Lancet 2008;371:1995; author reply 1996-7. [PMID: 18555906 DOI: 10.1016/S0140-6736(08)60860-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
36 Lee KM, Kim YS, Seo GS, Kim TO, Yang SK; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID). Intest Res. 2015;13:193-207. [PMID: 26130993 DOI: 10.5217/ir.2015.13.3.193] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
37 Flasar MH, Quezada S, Bijpuria P, Cross RK. Racial differences in disease extent and severity in patients with ulcerative colitis: a retrospective cohort study. Dig Dis Sci. 2008;53:2754-2760. [PMID: 18273704 DOI: 10.1007/s10620-007-0190-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
38 Herfarth HH, Kappelman MD, Long MD, Isaacs KL. Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases. Inflamm Bowel Dis 2016;22:224-33. [PMID: 26457382 DOI: 10.1097/MIB.0000000000000589] [Cited by in Crossref: 61] [Cited by in F6Publishing: 18] [Article Influence: 10.2] [Reference Citation Analysis]
39 Gomollón F, Gisbert JP. [Must immunomodulators be added to biological treatment in inflammatory bowel disease?]. Gastroenterol Hepatol 2010;33:43-53. [PMID: 19616870 DOI: 10.1016/j.gastrohep.2009.03.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
40 Khalif IL, Nanaeva BA, Golovenko AO, Golovenko OV. [Long-term results of medical treatment in patients with a severe attack of ulcerative colitis]. Ter Arkh 2015;87:34-8. [PMID: 25864346 DOI: 10.17116/terarkh201587234-38] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
41 Afif W, Loftus EV. Safety Profile of IBD Therapeutics: Infectious Risks. Gastroenterology Clinics of North America 2009;38:691-709. [DOI: 10.1016/j.gtc.2009.07.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
42 Nunes T, Barreiro-de Acosta M, Marin-Jiménez I, Nos P, Sans M. Oral locally active steroids in inflammatory bowel disease. J Crohns Colitis 2013;7:183-91. [PMID: 22784947 DOI: 10.1016/j.crohns.2012.06.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
43 Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, Kane SV, Sandborn WJ, Ullman TA, Moayyedi P. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011;106 Suppl 1:S2-S25; quiz S26. [PMID: 21472012 DOI: 10.1038/ajg.2011.58] [Cited by in Crossref: 177] [Cited by in F6Publishing: 165] [Article Influence: 16.1] [Reference Citation Analysis]
44 Liu Y, Zhou H. Budesonide-loaded guar gum microspheres for colon delivery: preparation, characterization and in vitro/in vivo evaluation. Int J Mol Sci 2015;16:2693-704. [PMID: 25629228 DOI: 10.3390/ijms16022693] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
45 Okayasu M, Ogata H, Yoshiyama Y. Use of corticosteroids for remission induction therapy in patients with new-onset ulcerative colitis in real-world settings. J Mark Access Health Policy 2019;7:1565889. [PMID: 30719244 DOI: 10.1080/20016689.2019.1565889] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
46 Baudet A, Rahmi G, Bretagne AL, Gloro R, Justum AM, Reimund JM. Severe ulcerative colitis: present medical treatment strategies. Expert Opin Pharmacother. 2008;9:447-457. [PMID: 18220494 DOI: 10.1517/14656566.9.3.447] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
47 Saibeni S, Bollani S, Losco A, Michielan A, Sostegni R, Devani M, Lupinacci G, Pirola L, Cucino C, Meucci G. The use of methotrexate for treatment of inflammatory bowel disease in clinical practice. Dig Liver Dis. 2012;44:123-127. [PMID: 22051323 DOI: 10.1016/j.dld.2011.09.015] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
48 Jiang XL, Cui HF. New treatments for refractory ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2011; 19(18): 1871-1873 [DOI: 10.11569/wcjd.v19.i18.1871] [Reference Citation Analysis]
49 Walsh A, Mabee J, Trivedi K. Inflammatory bowel disease. Prim Care. 2011;38:415-32; vii. [PMID: 21872089 DOI: 10.1016/j.pop.2011.06.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
50 Misdaq M, Ziegler S, von Ahsen N, Oellerich M, Asif AR. Thiopurines induce oxidative stress in T-lymphocytes: a proteomic approach. Mediators Inflamm. 2015;2015:434825. [PMID: 25873760 DOI: 10.1155/2015/434825] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
51 De Schepper HU, De Man JG, Moreels TG, Pelckmans PA, De Winter BY. Review article: gastrointestinal sensory and motor disturbances in inflammatory bowel disease - clinical relevance and pathophysiological mechanisms. Aliment Pharmacol Ther. 2008;27:621-637. [PMID: 18221407 DOI: 10.1111/j.1365-2036.2008.03624.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
52 Gisbert JP, Niño P, Cara C, Rodrigo L. Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients. Aliment Pharmacol Ther 2008;28:228-38. [PMID: 18485129 DOI: 10.1111/j.1365-2036.2008.03732.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 3.3] [Reference Citation Analysis]
53 Dassopoulos T, Sninsky CA. Optimizing Immunomodulators and Anti-TNF Agents in the Therapy of Crohn Disease. Gastroenterology Clinics of North America 2012;41:393-409. [DOI: 10.1016/j.gtc.2012.01.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
54 Pasternak B, Svanström H, Schmiegelow K, Jess T, Hviid A. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol. 2013;177:1296-1305. [PMID: 23514635 DOI: 10.1093/aje/kws375] [Cited by in Crossref: 124] [Cited by in F6Publishing: 106] [Article Influence: 13.8] [Reference Citation Analysis]
55 Epelboym Y, Shyn PB, Chick JFB, Hamilton MJ, O'connor SD, Silverman SG, Kim CK. Crohn Disease: FDG PET/CT Before and After Initial Dose of Anti–Tumor Necrosis Factor Therapy to Predict Long-term Response. Clin Nucl Med 2017;42:837-41. [DOI: 10.1097/rlu.0000000000001844] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Borniquel S, Jansson EA, Cole MP, Freeman BA, Lundberg JO. Nitrated oleic acid up-regulates PPARgamma and attenuates experimental inflammatory bowel disease. Free Radic Biol Med 2010;48:499-505. [PMID: 19932165 DOI: 10.1016/j.freeradbiomed.2009.11.014] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 4.5] [Reference Citation Analysis]
57 van Deen WK, van Oijen MG, Myers KD, Centeno A, Howard W, Choi JM, Roth BE, McLaughlin EM, Hollander D, Wong-Swanson B, Sack J, Ong MK, Ha CY, Esrailian E, Hommes DW. A nationwide 2010-2012 analysis of U.S. health care utilization in inflammatory bowel diseases. Inflamm Bowel Dis. 2014;20:1747-1753. [PMID: 25137415 DOI: 10.1097/mib.0000000000000139] [Cited by in Crossref: 46] [Cited by in F6Publishing: 21] [Article Influence: 6.6] [Reference Citation Analysis]
58 Askanase AD, Wallace DJ, Weisman MH, Tseng C, Bernstein L, Belmont HM, Seidman E, Ishimori M, Izmirly PM, Buyon JP. Use of Pharmacogenetics, Enzymatic Phenotyping, and Metabolite Monitoring to Guide Treatment with Azathioprine in Patients with Systemic Lupus Erythematosus. J Rheumatol 2009;36:89-95. [DOI: 10.3899/jrheum.070968] [Cited by in Crossref: 43] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
59 Direito R, Rocha J, Sepodes B, Eduardo-Figueira M. Phenolic Compounds Impact on Rheumatoid Arthritis, Inflammatory Bowel Disease and Microbiota Modulation. Pharmaceutics 2021;13:145. [PMID: 33499333 DOI: 10.3390/pharmaceutics13020145] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
60 Tripathi K, Feuerstein JD. New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance. Drugs Context 2019;8:212572. [PMID: 31065290 DOI: 10.7573/dic.212572] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
61 Armuzzi A, Pugliese D, Danese S, Rizzo G, Felice C, Marzo M, Andrisani G, Fiorino G, Sociale O, Papa A, De Vitis I, Rapaccini GL, Guidi L. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflamm Bowel Dis. 2013;19:1065-1072. [PMID: 23448790 DOI: 10.1097/mib.0b013e3182802909] [Cited by in Crossref: 53] [Cited by in F6Publishing: 21] [Article Influence: 5.9] [Reference Citation Analysis]
62 Annese V, Latiano A, Palmieri O, Andriulli A. Dissecting genetic predisposition to inflammatory bowel disease: current progress and prospective application. Expert Rev Clin Immunol 2007;3:287-98. [PMID: 20477673 DOI: 10.1586/1744666X.3.3.287] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
63 Navabi S, Gorrepati VS, Yadav S, Chintanaboina J, Maher S, Demuth P, Stern B, Stuart A, Tinsley A, Clarke K, Williams ED, Coates MD. Influences and Impact of Anxiety and Depression in the Setting of Inflammatory Bowel Disease. Inflamm Bowel Dis 2018;24:2303-8. [PMID: 29788469 DOI: 10.1093/ibd/izy143] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 12.3] [Reference Citation Analysis]
64 Abraham NS, Richardson P, Castillo D, Kane S. WITHDRAWN: Dual Therapy With Infliximab and Immunomodulator Reduces 1-Year Rates of Hospitalization and Surgery Among Veterans With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2013:S1542-3565(13)01042-2. [PMID: 23891919 DOI: 10.1016/j.cgh.2013.04.051] [Reference Citation Analysis]
65 Bianchi ML. Inflammatory bowel diseases, celiac disease, and bone. Arch Biochem Biophys 2010;503:54-65. [PMID: 20599670 DOI: 10.1016/j.abb.2010.06.026] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
66 Islam MS, Grainger SL. Do we know how to use corticosteroids in acute severe ulcerative colitis? Frontline Gastroenterol 2012;3:248-51. [PMID: 28839676 DOI: 10.1136/flgastro-2012-100211] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
67 Chang JY, Park SJ, Jung ES, Jung SA, Moon CM, Chun J, Park JJ, Kim ES, Park Y, Kim TI, Kim WH, Cheon JH. Genotype-based Treatment With Thiopurine Reduces Incidence of Myelosuppression in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2020; 18: 2010-2018. e2. [PMID: 31446180 DOI: 10.1016/j.cgh.2019.08.034] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
68 Bastida Paz G, Nos Mateu P, Aguas Peris M, Beltrán Niclós B, Rodríguez Soler M, Ponce García J. [Optimization of immunomodulatory treatment with azathioprine or 6-mercaptopurine in inflammatory bowel disease]. Gastroenterol Hepatol. 2007;30:511-516. [PMID: 17980127 DOI: 10.1157/13111681] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
69 Fan R, Zhong J, Wang ZT, Li SY, Zhou J, Tang YH. Evaluation of “top-down” treatment of early Crohn’s disease by double balloon enteroscopy. World J Gastroenterol 2014; 20(39): 14479-14487 [PMID: 25339835 DOI: 10.3748/wjg.v20.i39.14479] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
70 Tursi A, Mocci G, Allegretta L, Aragona G, Bianco MA, Colucci R, Cuomo A, Della Valle N, Ferronato A, Forti G, Gaiani F, Graziani MG, Lorenzetti R, Luzza F, Paese P, Penna A, Pica R, Pranzo G, Rodinò S, Scarcelli A, Zampaletta C, Brozzi L, Cicerone C, Cocco A, De' Angelis G, Donnarumma L, Fiorella S, Iannelli C, Larussa T, Le Grazie M, Luppino I, Meucci C, FaggianI R, Pagnini C, Perazzo P, Rodriguez-Castro KI, Sacco R, Sebkova L, Serio M, De Monti A, Picchio M, Napolitano D, Schiavoni E, Turchini L, Scaldaferri F, Pugliese D, Guidi L, Laterza L, Privitera G, Pizzoferrato M, Lopetuso LR, Armuzzi A, Elisei W, Maconi G, Papa A. Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy. Expert Opin Biol Ther 2021;:1-8. [PMID: 34904510 DOI: 10.1080/14712598.2022.2007881] [Reference Citation Analysis]
71 Navaneethan U, Shen B. Pros and cons of medical management of ulcerative colitis. Clin Colon Rectal Surg 2010;23:227-38. [PMID: 22131893 DOI: 10.1055/s-0030-1268249] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
72 Zhu M, Ran Z. Clinical characteristics of ulcerative colitis in elderly patients. JGH Open 2021;5:849-54. [PMID: 34386591 DOI: 10.1002/jgh3.12612] [Reference Citation Analysis]
73 Swaminath A, Kornbluth A. Optimizing drug therapy in inflammatory bowel disease. Curr Gastroenterol Rep 2007;9:513-20. [DOI: 10.1007/s11894-007-0068-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
74 Teml A, Schaeffeler E, Schwab M. Pretreatment determination of TPMT – state of the art in clinical practice. Eur J Clin Pharmacol 2009;65:219-21. [DOI: 10.1007/s00228-009-0618-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
75 Naeem M, Kim W, Cao J, Jung Y, Yoo JW. Enzyme/pH dual sensitive polymeric nanoparticles for targeted drug delivery to the inflamed colon. Colloids Surf B Biointerfaces 2014;123:271-8. [PMID: 25266978 DOI: 10.1016/j.colsurfb.2014.09.026] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
76 Travis S, Stange E, Lémann M, Øresland T, Bemelman W, Chowers Y, Colombel J, D'haens G, Ghosh S, Marteau P, Kruis W, Mortensen N, Penninckx F, Gassull M. European evidence-based Consensus on the management of ulcerative colitis: Current management. Journal of Crohn's and Colitis 2008;2:24-62. [DOI: 10.1016/j.crohns.2007.11.002] [Cited by in Crossref: 378] [Cited by in F6Publishing: 325] [Article Influence: 27.0] [Reference Citation Analysis]
77 Chumanevich AA, Chaparala A, Witalison EE, Tashkandi H, Hofseth AB, Lane C, Pena E, Liu P, Pittman DL, Nagarkatti P, Nagarkatti M, Hofseth LJ, Chumanevich AA. Looking for the best anti-colitis medicine: A comparative analysis of current and prospective compounds. Oncotarget 2017;8:228-37. [PMID: 27974688 DOI: 10.18632/oncotarget.13894] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
78 Gerster R, Eloranta JJ, Hausmann M, Ruiz PA, Cosin-Roger J, Terhalle A, Ziegler U, Kullak-Ublick GA, von Eckardstein A, Rogler G. Anti-inflammatory Function of High-Density Lipoproteins via Autophagy of IκB Kinase. Cell Mol Gastroenterol Hepatol 2015;1:171-187.e1. [PMID: 28247863 DOI: 10.1016/j.jcmgh.2014.12.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
79 Ghosh S, Bressler B, Petkau J, Thakkar RB, Wang S, Skup M, Chao J, Panaccione R, Schreiber S. Healthcare Providers Underestimate Patients’ Glucocorticoid Use in Crohn’s Disease. Dig Dis Sci 2019;64:1142-9. [DOI: 10.1007/s10620-018-5419-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
80 Gabbani T, Deiana S, Lunardi S, Manetti N, Annese V. Safety profile of methotrexate in inflammatory bowel disease. Expert Opinion on Drug Safety 2016;15:1427-37. [DOI: 10.1080/14740338.2016.1218468] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
81 Wang X, Wang G, Shang J, Pan H, Zhang XA, Zhou F. Immunosuppressive therapies adversely affect blood biochemical parameters in patients with inflammatory bowel disease: a meta-analysis. J Int Med Res 2019;47:3534-49. [PMID: 31364448 DOI: 10.1177/0300060519864800] [Reference Citation Analysis]
82 Chatu S, Subramanian V, Saxena S, Pollok RC. The role of thiopurines in reducing the need for surgical resection in Crohn’s disease: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109:23-34; quiz 35. [PMID: 24322839 DOI: 10.1038/ajg.2013.402] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 7.6] [Reference Citation Analysis]
83 Seto Y, Kato K, Tsukada R, Suzuki H, Kaneko Y, Kojo Y, Sato H, Onoue S. Protective effects of tranilast on experimental colitis in rats. Biomedicine & Pharmacotherapy 2017;90:842-9. [DOI: 10.1016/j.biopha.2017.04.035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
84 Sandborn WJ, Targan SR, Byers VS, Rutty DA, Mu H, Zhang X, Tang T. Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol. 2013;108:90-98. [PMID: 23044768 DOI: 10.1038/ajg.2012.340] [Cited by in Crossref: 87] [Cited by in F6Publishing: 75] [Article Influence: 8.7] [Reference Citation Analysis]
85 Caviglia R, Boškoski I, Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opinion on Drug Safety 2008;7:617-32. [DOI: 10.1517/14740338.7.5.617] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
86 Sandborn WJ. Initial combination therapy in early Crohn's disease. Lancet. 2008;371:635-636. [PMID: 18295013 DOI: 10.1016/S0140-6736(08)60285-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
87 de Graaf P, Vos RM, de Boer NH, Sinjewel A, Jharap B, Mulder CJ, van Bodegraven AA, Veldkamp AI. Limited stability of thiopurine metabolites in blood samples: relevant in research and clinical practise. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:1437-42. [PMID: 20399153 DOI: 10.1016/j.jchromb.2010.03.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
88 Nguyen GC, Harris ML, Dassopoulos T. Insights in immunomodulatory therapies for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep. 2006;8:499-505. [PMID: 17105689 DOI: 10.1007/s11894-006-0040-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
89 Ardizzone S, Cassinotti A, Manes G, Porro GB. Immunomodulators for all patients with inflammatory bowel disease? Therap Adv Gastroenterol. 2010;3:31-42. [PMID: 21180588 DOI: 10.1177/1756283x09354136] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
90 Relling MV, Schwab M, Whirl-Carrillo M, Suarez-Kurtz G, Pui CH, Stein CM, Moyer AM, Evans WE, Klein TE, Antillon-Klussmann FG, Caudle KE, Kato M, Yeoh AEJ, Schmiegelow K, Yang JJ. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105:1095-1105. [PMID: 30447069 DOI: 10.1002/cpt.1304] [Cited by in Crossref: 158] [Cited by in F6Publishing: 141] [Article Influence: 52.7] [Reference Citation Analysis]
91 Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305-353. [PMID: 29429045 DOI: 10.1007/s00535-018-1439-1] [Cited by in Crossref: 184] [Cited by in F6Publishing: 166] [Article Influence: 46.0] [Reference Citation Analysis]
92 Oussalah A, Roblin X, Laharie D, Filippi J, Flamant M, Faure P, Phelip J, Bigard M, Peyrin-biroulet L. Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey. Alimentary Pharmacology & Therapeutics 2009;30:854-63. [DOI: 10.1111/j.1365-2036.2009.4097.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
93 Wu XR, Liu XL, Katz S, Shen B. Pathogenesis, diagnosis, and management of ulcerative proctitis, chronic radiation proctopathy, and diversion proctitis. Inflamm Bowel Dis. 2015;21:703-715. [PMID: 25687266 DOI: 10.1097/mib.0000000000000227] [Cited by in Crossref: 30] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
94 Cross RK, Langenberg P, Regueiro M, Schwartz DA, Tracy JK, Collins JF, Katz J, Ghazi L, Patil SA, Quezada SM, Beaulieu D, Horst SN, Russman K, Riaz M, Jambaulikar G, Sivasailam B, Quinn CC. A Randomized Controlled Trial of TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD). Am J Gastroenterol 2019;114:472-82. [PMID: 30410041 DOI: 10.1038/s41395-018-0272-8] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 17.7] [Reference Citation Analysis]
95 Kono H, Fujii H, Ogiku M, Tsuchiya M, Ishii K, Hara M. Enteral diets enriched with medium-chain triglycerides and N-3 fatty acids prevent chemically induced experimental colitis in rats. Transl Res 2010;156:282-91. [PMID: 20970751 DOI: 10.1016/j.trsl.2010.07.012] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
96 Ye BD, Yang S, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim Y, Lee H; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Guidelines for the Management of Crohn's Disease. Intest Res 2012;10:26. [DOI: 10.5217/ir.2012.10.1.26] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
97 Sandborn WJ, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W; Study A3921043 Investigators. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014;12:1485-1493.e2. [PMID: 24480677 DOI: 10.1016/j.cgh.2014.01.029] [Cited by in Crossref: 178] [Cited by in F6Publishing: 170] [Article Influence: 22.3] [Reference Citation Analysis]
98 Shim TS. Diagnosis and Treatment of Latent Tuberculosis Infection due to Initiation of Anti-TNF Therapy. Tuberc Respir Dis (Seoul) 2014;76:261-8. [PMID: 25024719 DOI: 10.4046/trd.2014.76.6.261] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
99 López-Martín C, de la Fuente-Fernández E, Corbatón P, Sánchez MC, Gisbert JP. [Nodular regenerative hyperplasia: azathioprine-induced hepatotoxicity in a patient with Crohn's disease]. Gastroenterol Hepatol 2011;34:16-9. [PMID: 21168244 DOI: 10.1016/j.gastrohep.2010.10.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
100 Gisbert JP, Panés J. Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review. Am J Gastroenterol 2009;104:760-7. [DOI: 10.1038/ajg.2008.88] [Cited by in Crossref: 344] [Cited by in F6Publishing: 350] [Article Influence: 26.5] [Reference Citation Analysis]
101 Park JR, Pfeil SA. Primary Care of the Patient with Inflammatory Bowel Disease. Med Clin North Am 2015;99:969-87. [PMID: 26320042 DOI: 10.1016/j.mcna.2015.05.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
102 Teshima C, Fedorak RN. Are there differences in type, dosage, and method of administration for the systemic steroids in IBD treatment?: . Inflammatory Bowel Diseases 2008;14:S216-8. [DOI: 10.1002/ibd.20728] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
103 Vajravelu RK, Osterman MT, Aberra FN, Roy JA, Lichtenstein GR, Mamtani R, Goldberg DS, Lewis JD, Scott FI. Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization. Inflamm Bowel Dis 2017;24:217-26. [PMID: 29272482 DOI: 10.1093/ibd/izx019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
104 Gisbert JP, Linares PM, McNicholl AG, Maté J, Gomollón F. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther. 2009;30:126-137. [PMID: 19392869 DOI: 10.1111/j.1365-2036.2009.04023.x] [Cited by in Crossref: 139] [Cited by in F6Publishing: 120] [Article Influence: 10.7] [Reference Citation Analysis]
105 Nanaeva BA, Vardanyan AV, Khalif IL. [Efficiency of tacrolimus therapy for perianal Crohn's disease]. Ter Arkh 2015;87:83-7. [PMID: 26281201 DOI: 10.17116/terarkh201587683-87] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
106 da Costa Gonçalves F, Paz AH. Cell membrane and bioactive factors derived from mesenchymal stromal cells: Cell-free based therapy for inflammatory bowel diseases. World J Stem Cells 2019; 11(9): 618-633 [PMID: 31616539 DOI: 10.4252/wjsc.v11.i9.618] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
107 Zhou X, Lu Q, Kang X, Tian G, Ming D, Yang J. Protective Role of a New Polysaccharide Extracted from Lonicera japonica Thunb in Mice with Ulcerative Colitis Induced by Dextran Sulphate Sodium. Biomed Res Int 2021;2021:8878633. [PMID: 33490281 DOI: 10.1155/2021/8878633] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
108 Hanauer SB. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut 2007;56:1181-3. [PMID: 17698862 DOI: 10.1136/gut.2006.115980] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
109 Andrews JM. Le plus ca change: Why we need better biomarkers to predict outcomes in ulcerative colitis: Editorials. Journal of Gastroenterology and Hepatology 2011;26:1085-6. [DOI: 10.1111/j.1440-1746.2011.06754.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
110 Vaughn BP, Doherty GA, Gautam S, Moss AC, Cheifetz AS. Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. Inflamm Bowel Dis. 2012;18:1057-1063. [PMID: 21953829 DOI: 10.1002/ibd.21824] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
111 Flasar MH, Johnson T, Roghmann M, Cross RK. Disparities in the use of immunomodulators and biologics for the treatment of inflammatory bowel disease: A retrospective cohort study: . Inflammatory Bowel Diseases 2008;14:13-9. [DOI: 10.1002/ibd.20298] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
112 Kim HS, Cheon JH, Jung ES, Park J, Aum S, Park SJ, Eun S, Lee J, Rüther U, Yeo GSH, Ma M, Park KS, Naito T, Kakuta Y, Lee JH, Kim WH, Lee MG. A coding variant in FTO confers susceptibility to thiopurine-induced leukopenia in East Asian patients with IBD. Gut 2017;66:1926-35. [PMID: 27558924 DOI: 10.1136/gutjnl-2016-311921] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
113 Kondamudi PK, Kovelamudi H, Mathew G, Nayak PG, Rao MC, Shenoy RR. Investigation of sesamol on myeloperoxidase and colon morphology in acetic acid-induced inflammatory bowel disorder in albino rats. ScientificWorldJournal 2014;2014:802701. [PMID: 24616646 DOI: 10.1155/2014/802701] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
114 Lanzoni G, Roda G, Belluzzi A, Roda E, Bagnara GP. Inflammatory bowel disease: Moving toward a stem cell-based therapy. World J Gastroenterol 2008; 14(29): 4616-4626 [PMID: 18698675 DOI: 10.3748/wjg.14.4616] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.4] [Reference Citation Analysis]
115 Vasudevan A, Gibson PR, Langenberg DRV. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told? World J Gastroenterol 2017; 23(35): 6385-6402 [PMID: 29085188 DOI: 10.3748/wjg.v23.i35.6385] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
116 Fukuda T, Majumder K, Zhang H, Turner PV, Matsui T, Mine Y. Adenine Inhibits TNF-α Signaling in Intestinal Epithelial Cells and Reduces Mucosal Inflammation in a Dextran Sodium Sulfate-Induced Colitis Mouse Model. J Agric Food Chem 2016;64:4227-34. [DOI: 10.1021/acs.jafc.6b00665] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
117 Meier C, Plevy S. Therapy Insight: how the gut talks to the joints—inflammatory bowel disease and the spondyloarthropathies. Nat Rev Rheumatol 2007;3:667-74. [DOI: 10.1038/ncprheum0625] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
118 Ripollés T, Martínez MJ, Paredes JM, Blanc E, Flors L, Delgado F. Crohn disease: correlation of findings at contrast-enhanced US with severity at endoscopy. Radiology. 2009;253:241-248. [PMID: 19635834 DOI: 10.1148/radiol.2531082269] [Cited by in Crossref: 109] [Cited by in F6Publishing: 94] [Article Influence: 8.4] [Reference Citation Analysis]
119 Gardiner SJ, Gearry RB, Begg EJ, Zhang M, Barclay ML. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clin Gastroenterol Hepatol 2008;6:654-60; quiz 604. [PMID: 18467186 DOI: 10.1016/j.cgh.2008.02.032] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 4.1] [Reference Citation Analysis]
120 Matsuno Y, Hirano A, Torisu T, Okamoto Y, Fuyuno Y, Fujioka S, Umeno J, Moriyama T, Nagai S, Hori Y, Fujiwara M, Kitazono T, Esaki M. Short-term and long-term outcomes of indigo naturalis treatment for inflammatory bowel disease. J Gastroenterol Hepatol 2020;35:412-7. [PMID: 31389626 DOI: 10.1111/jgh.14823] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
121 Schluender SJ, Ippoliti A, Dubinsky M, Vasiliauskas EA, Papadakis KA, Mei L, Targan SR, Fleshner PR. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum. 2007;50:1747-1753. [PMID: 17704969 DOI: 10.1007/s10350-007-9008-3] [Cited by in Crossref: 97] [Cited by in F6Publishing: 84] [Article Influence: 6.9] [Reference Citation Analysis]
122 Moreau AC, Paul S, Del Tedesco E, Rinaudo-Gaujous M, Boukhadra N, Genin C, Peyrin-Biroulet L, Roblin X. Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: a meta-analysis. Inflamm Bowel Dis. 2014;20:464-471. [PMID: 24418904 DOI: 10.1097/01.mib.0000439068.71126.00] [Cited by in Crossref: 67] [Cited by in F6Publishing: 19] [Article Influence: 8.4] [Reference Citation Analysis]
123 Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, Joseph R. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2009;15:1-8. [PMID: 18671232 DOI: 10.1002/ibd.20580] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 4.7] [Reference Citation Analysis]
124 Hanauer SB. Review article: evolving concepts in treatment and disease modification in ulcerative colitis. Aliment Pharmacol Ther. 2008;27 Suppl 1:15-21. [PMID: 18307645 DOI: 10.1111/j.1365-2036.2008.03606.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
125 Ooi CJ, Makharia GK, Hilmi I, Gibson PR, Fock KM, Ahuja V, Ling KL, Lim WC, Thia KT, Wei SC, Leung WK, Koh PK, Gearry RB, Goh KL, Ouyang Q, Sollano J, Manatsathit S, de Silva HJ, Rerknimitr R, Pisespongsa P, Abu Hassan MR, Sung J, Hibi T, Boey CC, Moran N, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease. Asia-Pacific consensus statements on Crohn's disease. Part 2: Management. J Gastroenterol Hepatol. 2016;31:56-68. [PMID: 25819311 DOI: 10.1111/jgh.12958] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
126 Chang JY, Cheon JH. Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics. Dig Dis Sci 2019;64:2395-403. [PMID: 31290039 DOI: 10.1007/s10620-019-05720-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
127 Herfarth HH, Long MD, Isaacs KL. Methotrexate: underused and ignored? Dig Dis 2012;30 Suppl 3:112-8. [PMID: 23295701 DOI: 10.1159/000342735] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
128 Azuma K, Osaki T, Wakuda T, Ifuku S, Saimoto H, Tsuka T, Imagawa T, Okamoto Y, Minami S. Beneficial and preventive effect of chitin nanofibrils in a dextran sulfate sodium-induced acute ulcerative colitis model. Carbohydrate Polymers 2012;87:1399-403. [DOI: 10.1016/j.carbpol.2011.09.036] [Cited by in Crossref: 44] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
129 Gazouli M, Pachoula I, Panayotou I, Chouliaras G, Anagnou NP, Chroussos G, Roma E. Thiopurine methyltransferase genotype and thiopurine S-methyltransferase activity in Greek children with inflammatory bowel disease. Ann Gastroenterol. 2012;25:249-253. [PMID: 24714152 DOI: 10.1016/s1873-9946(12)60248-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
130 Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641-1657. [PMID: 17499606 DOI: 10.1016/s0140-6736(07)60751-x] [Cited by in Crossref: 1121] [Cited by in F6Publishing: 487] [Article Influence: 74.7] [Reference Citation Analysis]
131 Mehta SJ, Silver AR, Lindsay JO. Review article: strategies for the management of chronic unremitting ulcerative colitis. Aliment Pharmacol Ther 2013;38:77-97. [DOI: 10.1111/apt.12345] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
132 Naganuma M, Fujii T, Watanabe M. The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. J Gastroenterol. 2011;46:129-137. [PMID: 21132334 DOI: 10.1007/s00535-010-0352-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
133 Shim TS. Diagnosis and Treatment of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Diseases due to Initiation of Anti-Tumor Necrosis Factor Therapy. Intest Res 2014;12:12-9. [PMID: 25349559 DOI: 10.5217/ir.2014.12.1.12] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
134 Oliva-hemker M, Escher J, Moore D, Dubinksy M, Hildebrand H, Koda Y, Murch S, Sandhu B, Seo J, Tanzi M, Warner B. Refractory Inflammatory Bowel Disease in Children. Journal of Pediatric Gastroenterology & Nutrition 2008;47:266-72. [DOI: 10.1097/mpg.0b013e318181b48c] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
135 Blonski W, Buchner AM, Lichtenstein GR. Inflammatory bowel disease therapy: current state-of-the-art. Curr Opin Gastroenterol 2011;27:346-57. [PMID: 21654383 DOI: 10.1097/MOG.0b013e328347aef3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
136 Louis E. Thiopurine metabolites and TPMT activity measurement in inflammatory bowel disease: Letters to the Editors. Alimentary Pharmacology & Therapeutics 2011;34:1138-9. [DOI: 10.1111/j.1365-2036.2011.04804.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
137 Lau A, Chande N, Ponich T, Gregor JC. Predictive factors associated with immunosuppressive agent use in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2008;28:606-613. [PMID: 18564323 DOI: 10.1111/j.1365-2036.2008.03772.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
138 Orlando A, Mocciaro F, Civitavecchia G, Scimeca D, Cottone M. Minimizing infliximab toxicity in the treatment of inflammatory bowel disease. Digestive and Liver Disease 2008;40:S236-46. [DOI: 10.1016/s1590-8658(08)60532-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
139 Tu T, Yu M, Zhang Y, Shi X, Xu J, Hu J, Gan J, He W, Dong L, Han J, Huang Z, Pan Y, Zhang J. A novel fluorinated triazole derivative suppresses macrophage activation and alleviates experimental colitis via a Twist1-dependent pathway. Biochemical Pharmacology 2018;155:275-87. [DOI: 10.1016/j.bcp.2018.07.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
140 Park MS, Kim DH, Kim DH, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Leukopenia predicts remission in patients with inflammatory bowel disease and Behcet's disease on thiopurine maintenance. Dig Dis Sci 2015;60:195-204. [PMID: 25239495 DOI: 10.1007/s10620-014-3355-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
141 Hicks CW, Wick EC, Salvatori R, Ha CY. Perioperative Corticosteroid Management for Patients with Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2015;21:221-8. [DOI: 10.1097/mib.0000000000000185] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
142 Brazilian Study Group of Inflammatory Bowel Diseases. Consensus guidelines for the management of inflammatory bowel disease. Arq Gastroenterol. 2010;47:313-325. [PMID: 21140096 DOI: 10.1590/s0004-28032010000300019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
143 Vavricka SR, Schoepfer AM, Scharl M, Rogler G. Steroid Use in Crohn’s Disease. Drugs 2014;74:313-24. [DOI: 10.1007/s40265-014-0183-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
144 Wong DD, Forbes GM, Zelesco M, Mason R, Pawlik J, Mendelson RM. Crohn's disease activity: quantitative contrast-enhanced ultrasound assessment. Abdom Imaging 2012;37:369-76. [PMID: 21830051 DOI: 10.1007/s00261-011-9792-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
145 Blonski W, Buchner AM, Lichtenstein GR. Treatment of ulcerative colitis. Curr Opin Gastroenterol. 2014;30:84-96. [PMID: 24285003 DOI: 10.1097/mog.0000000000000031] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
146 Tursi A, Elisei W, Picchio M, Giorgetti G, Brandimarte G. Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists. Dig Dis Sci 2015;60:1406-13. [PMID: 25445163 DOI: 10.1007/s10620-014-3459-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
147 Kochi S, Matsumoto T, Esaki M, Jo Y, Iida M. Prediction of 6-thioguanine nucleotides levels in Japanese patients with inflammatory bowel diseases during long-term thiopurine administration. Scand J Gastroenterol 2010;45:608-14. [PMID: 20163203 DOI: 10.3109/00365521003642559] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
148 Schwartz M, Cohen R. Optimizing conventional therapy for inflammatory bowel disease. Curr Gastroenterol Rep 2008;10:585-90. [PMID: 19006615 DOI: 10.1007/s11894-008-0106-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
149 Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28:674-688. [PMID: 18532990 DOI: 10.1111/j.1365-2036.2008.03753.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 4.9] [Reference Citation Analysis]
150 Epstein D, Watermeyer G, Kirsch R. Review article: the diagnosis and management of Crohn's disease in populations with high-risk rates for tuberculosis. Aliment Pharmacol Ther 2007;25:1373-88. [PMID: 17539977 DOI: 10.1111/j.1365-2036.2007.03332.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 65] [Article Influence: 5.3] [Reference Citation Analysis]
151 Bossa F, Latiano A, Rossi L, Magnani M, Palmieri O, Dallapiccola B, Serafini S, Damonte G, De Santo E, Andriulli A. Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. Am J Gastroenterol. 2008;103:2509-2516. [PMID: 18721243 DOI: 10.1111/j.1572-0241.2008.02103.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 3.9] [Reference Citation Analysis]
152 Akiho H, Yokoyama A, Abe S, Nakazono Y, Murakami M, Otsuka Y, Fukawa K, Esaki M, Niina Y, Ogino H. Promising biological therapies for ulcerative colitis: A review of the literature. World J Gastrointest Pathophysiol 2015; 6(4): 219-227 [PMID: 26600980 DOI: 10.4291/wjgp.v6.i4.219] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
153 Saibeni S, Kohn A, Meucci G, Papi C; Italian Group for Inflammatory Bowel Disease. How thiopurines are used for the treatment of inflammatory bowel diseases: an Italian survey. Dig Liver Dis 2015;47:170-3. [PMID: 25467827 DOI: 10.1016/j.dld.2014.10.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
154 Broekman MMTJ, Coenen MJH, Wanten GJ, van Marrewijk CJ, Klungel OH, Verbeek ALM, Hooymans PM, Guchelaar HJ, Scheffer H, Derijks LJJ, Wong DR, de Jong DJ. Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype. Aliment Pharmacol Ther 2017;46:953-63. [PMID: 28914446 DOI: 10.1111/apt.14323] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
155 Hashash JG, Chintamaneni P, Ramos Rivers CM, Koutroubakis IE, Regueiro MD, Baidoo L, Swoger JM, Barrie A, Schwartz M, Dunn MA, Binion DG. Patterns of Antibiotic Exposure and Clinical Disease Activity in Inflammatory Bowel Disease: A 4-year Prospective Study. Inflamm Bowel Dis 2015;21:2576-82. [PMID: 26296061 DOI: 10.1097/MIB.0000000000000534] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
156 Taylor K, Gibson PR. Conventional Therapy of Ulcerative Colitis: Corticosteroids. In: Baumgart DC, editor. Crohn's Disease and Ulcerative Colitis. Cham: Springer International Publishing; 2017. pp. 399-412. [DOI: 10.1007/978-3-319-33703-6_39] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
157 Lanzoni G, Roda G, Belluzzi A, Roda E, Bagnara GP. Inflammatory bowel disease: Moving toward a stem cell-based therapy. World J Gastroenterol. 2008;14:4616-4626. [PMID: 18698675 DOI: 10.3748/wjp.14.4616] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
158 Bermejo F, López-Sanromán A, Algaba A, Van-Domselaar M, Gisbert JP, García-Garzón S, Garrido E, Piqueras B, De La Poza G, Guerra I. Mercaptopurine rescue after azathioprine-induced liver injury in inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31:120-124. [PMID: 19709096 DOI: 10.1111/j.1365-2036.2009.04132.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
159 Manz M, Vavricka SR, Wanner R, Lakatos PL, Rogler G, Frei P, Safroneeva E, Schoepfer AM. Therapy of steroid-resistant inflammatory bowel disease. Digestion. 2012;86 Suppl 1:11-15. [PMID: 23051721 DOI: 10.1159/000341952] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
160 Kondamudi PK, Kovelamudi H, Nayak PG, Rao MC, Shenoy RR. Curcumin half analog modulates interleukin-6 and tumor necrosis factor-alpha in inflammatory bowel disease. Pharmacogn Mag 2015;11:S296-302. [PMID: 26664018 DOI: 10.4103/0973-1296.165991] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
161 Qian X, Wang T, Shen J, Ran Z. Low dose of azathioprine is effective to induce and maintain remission in active Crohn disease: A prospective observational study. Medicine (Baltimore) 2018;97:e11814. [PMID: 30142769 DOI: 10.1097/MD.0000000000011814] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
162 Dulai PS, Osterman MT, Lasch K, Cao C, Riaz F, Sandborn WJ. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies. Dig Dis Sci 2019;64:2478-88. [PMID: 30923985 DOI: 10.1007/s10620-019-05594-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
163 Chouchana L, Narjoz C, Beaune P, Loriot M, Roblin X. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease: Review: pharmacogenetics of thiopurines in IBD. Alimentary Pharmacology & Therapeutics 2012;35:15-36. [DOI: 10.1111/j.1365-2036.2011.04905.x] [Cited by in Crossref: 111] [Cited by in F6Publishing: 97] [Article Influence: 10.1] [Reference Citation Analysis]
164 Tamboli CP. Current Medical Therapy for Chronic Inflammatory Bowel Diseases. Surgical Clinics of North America 2007;87:697-725. [DOI: 10.1016/j.suc.2007.03.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
165 Ye JH, Rajendran VM. Adenosine: An immune modulator of inflammatory bowel diseases. World J Gastroenterol 2009; 15(36): 4491-4498 [PMID: 19777607 DOI: 10.3748/wjg.15.4491] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 44] [Article Influence: 3.2] [Reference Citation Analysis]
166 Ye BD, Yang SK, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim YH, Lee H. [Guidelines for the management of Crohn’s disease]. Korean J Gastroenterol. 2012;59:141-179. [PMID: 22387837 DOI: 10.4166/kjg.2012.59.2.141] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
167 Danese S, Colombel JF, Reinisch W, Rutgeerts PJ. Review article: infliximab for Crohn's disease treatment--shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther 2011;33:857-69. [PMID: 21320139 DOI: 10.1111/j.1365-2036.2011.04598.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 5.1] [Reference Citation Analysis]
168 Sandborn WJ, Feagan BG, Loftus EV Jr, Peyrin-Biroulet L, Van Assche G, D'Haens G, Schreiber S, Colombel JF, Lewis JD, Ghosh S, Armuzzi A, Scherl E, Herfarth H, Vitale L, Mohamed MF, Othman AA, Zhou Q, Huang B, Thakkar RB, Pangan AL, Lacerda AP, Panes J. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. Gastroenterology 2020;158:2123-2138.e8. [PMID: 32044319 DOI: 10.1053/j.gastro.2020.01.047] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 20.0] [Reference Citation Analysis]
169 Joo M, Odze RD. Rectal sparing and skip lesions in ulcerative colitis: a comparative study of endoscopic and histologic findings in patients who underwent proctocolectomy. Am J Surg Pathol. 2010;34:689-696. [PMID: 20410806 DOI: 10.1097/pas.0b013e3181db84cd] [Cited by in Crossref: 58] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
170 Bokemeyer B, Teml A, Roggel C, Hartmann P, Fischer C, Schaeffeler E, Schwab M. Adherence to thiopurine treatment in out-patients with Crohn's disease. Aliment Pharmacol Ther 2007;26:217-25. [PMID: 17593067 DOI: 10.1111/j.1365-2036.2007.03365.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 3.3] [Reference Citation Analysis]
171 de Boer NK, van Bodegraven AA, Jharap B, de Graaf P, Mulder CJ. Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Rev Gastroenterol Hepatol 2007;4:686-94. [DOI: 10.1038/ncpgasthep1000] [Cited by in Crossref: 84] [Cited by in F6Publishing: 79] [Article Influence: 5.6] [Reference Citation Analysis]
172 Dewit O, Moreels T, Baert F, Peeters H, Reenaers C, de Vos M, Van Hootegem P, Muls V, Veereman G, Mana F, Van Outryve M, Holvoet J, Naegels S, Piessevaux H, Horsmans Y, Gala JL; Belgian Inflammatory Bowel Disease Research Group (BIRD). Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patients. Clin Biochem 2011;44:1062-6. [PMID: 21723857 DOI: 10.1016/j.clinbiochem.2011.06.079] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
173 Dave M, Purohit T, Razonable R, Loftus EV. Opportunistic infections due to inflammatory bowel disease therapy. Inflamm Bowel Dis. 2014;20:196-212. [PMID: 24051931 DOI: 10.1097/mib.0b013e3182a827d2] [Cited by in Crossref: 75] [Cited by in F6Publishing: 30] [Article Influence: 9.4] [Reference Citation Analysis]
174 Vasudevan A, Parthasarathy N, Con D, Nicolaides S, Apostolov R, Chauhan A, Bishara M, Luber RP, Joshi N, Wan A, Rickard JA, Long T, Connoley D, Sparrow MP, Gibson PR, van Langenberg DR. Thiopurines vs methotrexate: Comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2020;52:1174-84. [PMID: 32794599 DOI: 10.1111/apt.16039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
175 Molnár T, Farkas K, Miheller P, Nyári T, Szepes Z, Herszényi L, Müzes G, Nagy F, Tulassay Z, Wittmann T. Is the efficacy of successful infliximab induction therapy maintained for one year lasting without retreatment in different behavior types of Crohn’s disease? J Crohns Colitis. 2008;2:322-326. [PMID: 21172231 DOI: 10.1016/j.crohns.2008.07.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
176 Panés J, D'Haens GR, Higgins PDR, Mele L, Moscariello M, Chan G, Wang W, Niezychowski W, Su C, Maller E. Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study. Aliment Pharmacol Ther 2019;49:265-76. [PMID: 30663107 DOI: 10.1111/apt.15072] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
177 Boirivant M, Cossu A. Inflammatory bowel disease. Oral Dis. 2012;18:1-15. [PMID: 21564424 DOI: 10.1111/j.1601-0825.2011.01811.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
178 Collnot EM, Ali H, Lehr CM. Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. J Control Release. 2012;161:235-246. [PMID: 22306429 DOI: 10.1016/j.jconrel.2012.01.028] [Cited by in Crossref: 141] [Cited by in F6Publishing: 128] [Article Influence: 14.1] [Reference Citation Analysis]
179 Picco MF. Everything old is new again? A fresh look at corticosteroids in ulcerative colitis. Am J Gastroenterol 2008;103:2517-8. [PMID: 18855853 DOI: 10.1111/j.1572-0241.2008.02112.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
180 Shrestha MP, Taleban S. Management of Ulcerative Colitis in the Elderly. Drugs Aging 2019;36:13-27. [DOI: 10.1007/s40266-018-0611-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
181 Lichtenstein GR, Hanauer SB, Sandborn WJ; Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104:465-83; quiz 464, 484. [PMID: 19174807 DOI: 10.1038/ajg.2008.168] [Cited by in Crossref: 606] [Cited by in F6Publishing: 516] [Article Influence: 46.6] [Reference Citation Analysis]
182 Flasar MH, Chao J, Ozbay AB, Skup M, Lu M, Cross R. Biological and Immunomodulator Use in Crohnʼs Disease in a Medicaid Population: . Inflammatory Bowel Diseases 2016;22:1056-64. [DOI: 10.1097/mib.0000000000000730] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
183 Xu X, Cao Z, Li X, Tao D, Hu J, Yang C, Gong J. Injecting drugs by a tube from appendix stump to colon may be a good method for dealing with refractory ulcerative colitis. Med Hypotheses 2010;74:631-3. [PMID: 19932937 DOI: 10.1016/j.mehy.2009.10.042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
184 Evans PE, Pardi DS. Inflammatory bowel disease in the elderly. Aging Health 2007;3:77-84. [DOI: 10.2217/1745509x.3.1.77] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
185 Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet. 2007;46:187-208. [PMID: 17328579 DOI: 10.2165/00003088-200746030-00001] [Cited by in Crossref: 116] [Cited by in F6Publishing: 99] [Article Influence: 7.7] [Reference Citation Analysis]
186 Chumanevich AA, Causey CP, Knuckley BA, Jones JE, Poudyal D, Chumanevich AP, Davis T, Matesic LE, Thompson PR, Hofseth LJ. Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor. Am J Physiol Gastrointest Liver Physiol 2011;300:G929-38. [PMID: 21415415 DOI: 10.1152/ajpgi.00435.2010] [Cited by in Crossref: 116] [Cited by in F6Publishing: 120] [Article Influence: 10.5] [Reference Citation Analysis]
187 Sadowski DC, Bernstein CN, Bitton A, Croitoru K, Fedorak RN, Griffiths A; CAG Crohn's Consensus Group. Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. Can J Gastroenterol 2009;23:185-202. [PMID: 19319383 DOI: 10.1155/2009/201430] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
188 Herfarth H. Are we ready for top-down therapy for inflammatory bowel diseases: con. Expert Review of Gastroenterology & Hepatology 2014;1:249-55. [DOI: 10.1586/17474124.1.2.249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
189 Chebli LA, Chaves LD, Pimentel FF, Guerra DM, Barros RM, Gaburri PD, Zanini A, Chebli JM. Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis. Inflamm Bowel Dis. 2010;16:613-619. [PMID: 19705415 DOI: 10.1002/ibd.21083] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 4.1] [Reference Citation Analysis]
190 Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007;46:645-60. [PMID: 17655372 DOI: 10.2165/00003088-200746080-00002] [Cited by in Crossref: 166] [Cited by in F6Publishing: 144] [Article Influence: 11.1] [Reference Citation Analysis]
191 Abegunde AT, Muhammad BH, Ali T. Preventive health measures in inflammatory bowel disease. World J Gastroenterol 2016; 22(34): 7625-7644 [PMID: 27678347 DOI: 10.3748/wjg.v22.i34.7625] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
192 Gisbert JP, Gomollón F. Common Misconceptions in the Diagnosis and Management of Anemia in Inflammatory Bowel Disease. Am J Gastroenterology 2008;103:1299-307. [DOI: 10.1111/j.1572-0241.2008.01846.x] [Cited by in Crossref: 132] [Cited by in F6Publishing: 127] [Article Influence: 9.4] [Reference Citation Analysis]
193 Kuhbacher T, Fölsch U. Practical guidelines for the treatment of inflammatory bowel disease. World J Gastroenterol 2007; 13(8): 1149-1155 [PMID: 17451192 DOI: 10.3748/wjg.v13.i8.1149] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
194 Caviglia R, Boskoski I, Cicala M. Maintenance treatment with infliximab for the management of Crohn's disease in adults. Biologics 2009;3:39-49. [PMID: 19707394 DOI: 10.2147/btt.2009.2763] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
195 Teshima C, Fedorak RN. Are there differences in type, dosage, and method of administration for the systemic steroids in IBD treatment?: . Inflammatory Bowel Diseases 2008;14:S216-8. [DOI: 10.1097/00054725-200810001-00102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
196 Panaccione R, Steinhart AH, Bressler B, Khanna R, Marshall JK, Targownik L, Afif W, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV Jr, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C, Bernstein CN. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. J Can Assoc Gastroenterol 2019;2:e1-e34. [PMID: 31294378 DOI: 10.1093/jcag/gwz019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
197 Dorrington AM, Selinger CP, Parkes GC, Smith M, Pollok RC, Raine T. The Historical Role and Contemporary Use of Corticosteroids in Inflammatory Bowel Disease. J Crohns Colitis. 2020;14:1316-1329. [PMID: 32170314 DOI: 10.1093/ecco-jcc/jjaa053] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
198 Azzman N. Crohn's Disease: Potential Drugs for Modulation of Autophagy. Medicina (Kaunas) 2019;55:E224. [PMID: 31146413 DOI: 10.3390/medicina55060224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
199 Juillerat P, Vader J, Felley C, Pittet V, Gonvers J, Mottet C, Bemelman WA, Lémann M, Öresland T, Michetti P, Froehlich F. Appropriate maintenance treatment for Crohn's disease: Results of a multidisciplinary international expert panel — EPACT II. Journal of Crohn's and Colitis 2009;3:241-9. [DOI: 10.1016/j.crohns.2009.05.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
200 Paredes JM, Ripollés T, Cortés X, Martínez MJ, Barrachina M, Gómez F, Moreno-Osset E. Abdominal sonographic changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's Disease. Dig Dis Sci 2010;55:404-10. [PMID: 19267199 DOI: 10.1007/s10620-009-0759-7] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
201 Borrelli F, Aviello G, Romano B, Orlando P, Capasso R, Maiello F, Guadagno F, Petrosino S, Capasso F, Di Marzo V, Izzo AA. Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J Mol Med (Berl). 2009;87:1111-1121. [PMID: 19690824 DOI: 10.1007/s00109-009-0512-x] [Cited by in Crossref: 105] [Cited by in F6Publishing: 106] [Article Influence: 8.1] [Reference Citation Analysis]
202 Yamamoto T, Umegae S, Matsumoto K. Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn’s disease: a prospective pilot study. Inflamm Bowel Dis. 2009;15:1460-1466. [PMID: 19266566 DOI: 10.1002/ibd.20915] [Cited by in Crossref: 88] [Cited by in F6Publishing: 78] [Article Influence: 6.8] [Reference Citation Analysis]
203 Ong DE, Kamm MA, Hartono JL, Lust M. Addition of thiopurines can recapture response in patients with Crohn’s disease who have lost response to anti-tumor necrosis factor monotherapy. J Gastroenterol Hepatol. 2013;28:1595-1599. [PMID: 23662928 DOI: 10.1111/jgh.12263] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
204 Benchimol EI, Seow CH, Steinhart AH, Griffiths AM. Traditional corticosteroids for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008;CD006792. [PMID: 18425970 DOI: 10.1002/14651858.cd006792] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
205 Coskun M, Salem M, Pedersen J, Nielsen OH. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res. 2013;76:1-8. [PMID: 23827161 DOI: 10.1016/j.phrs.2013.06.007] [Cited by in Crossref: 160] [Cited by in F6Publishing: 154] [Article Influence: 17.8] [Reference Citation Analysis]
206 Salice M, Rizzello F, Calabrese C, Calandrini L, Gionchetti P. A current overview of corticosteroid use in active ulcerative colitis. Expert Rev Gastroenterol Hepatol 2019;13:557-61. [PMID: 30947569 DOI: 10.1080/17474124.2019.1604219] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
207 Gisbert JP, Gomollón F. [Common errors in the management of the seriously ill patient with inflammatory bowel disease]. Gastroenterol Hepatol 2007;30:294-314. [PMID: 17493441 DOI: 10.1157/13101982] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
208 Cabrera JM, Sato TT. Medical and Surgical Management of Pediatric Ulcerative Colitis. Clin Colon Rectal Surg 2018;31:71-9. [PMID: 29487489 DOI: 10.1055/s-0037-1609021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
209 Velayos F, Mahadevan U. Management of steroid-dependent ulcerative colitis: immunomodulatory agents, biologics, or surgery? Clin Gastroenterol Hepatol 2007;5:668-71. [PMID: 17544992 DOI: 10.1016/j.cgh.2007.03.028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
210 Suzuki Y, Matsui T, Ito H, Ashida T, Nakamura S, Motoya S, Matsumoto T, Sato N, Ozaki K, Watanabe M, Hibi T. Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohnʼs Disease: A Prospective Clinical Trial. Inflammatory Bowel Diseases 2015;21:2114-22. [DOI: 10.1097/mib.0000000000000475] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
211 Sjöberg M, Walch A, Meshkat M, Gustavsson A, Järnerot G, Vogelsang H, Hertervig E, Novacek G, Friis-Liby I, Blomquist L. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study. Inflamm Bowel Dis. 2012;18:212-218. [PMID: 21438096 DOI: 10.1002/ibd.21680] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
212 Greenberg R, Greenwald B, Roth JS, Ioffe O, Cross R. Squamous dysplasia of the rectum in a patient with ulcerative colitis treated with 6-mercaptopurine. Dig Dis Sci. 2008;53:760-764. [PMID: 17717741 DOI: 10.1007/s10620-007-9935-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
213 Andrisani G, Armuzzi A, Marzo M, Felice C, Pugliese D, Papa A, Guidi L. What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? World J Gastrointest Pharmacol Ther 2016; 7(3): 387-396 [PMID: 27602239 DOI: 10.4292/wjgpt.v7.i3.387] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
214 Davies SC, Hussein IM, Nguyen TM, Parker CE, Khanna R, Jairath V. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2020;1:CD012381. [PMID: 31984480 DOI: 10.1002/14651858.CD012381.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
215 Behm BW, Bickston SJ. Efficacy of infliximab for luminal and fistulizing Crohn's disease and in ulcerative colitis. Curr Treat Options Gastroenterol. 2007;10:171-177. [PMID: 17547855 DOI: 10.1007/s11938-007-0010-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
216 Taxonera C, Rodrigo L, Casellas F, Calvet X, Gómez-Camacho F, Ginard D, Castro M, Castro L, Ponce M, Martínez-Montiel P, Ricart E, Gisbert JP, López-San Román A, Morales JM, Casado MA. Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's disease. J Clin Gastroenterol 2009;43:950-6. [PMID: 19448569 DOI: 10.1097/MCG.0b013e3181986917] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
217 Timmer A, McDonald JW, Tsoulis DJ, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;CD000478. [PMID: 22972046 DOI: 10.1002/14651858.cd000478.pub3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 43] [Article Influence: 3.5] [Reference Citation Analysis]
218 Baumgart DC. The diagnosis and treatment of Crohn's disease and ulcerative colitis. Dtsch Arztebl Int. 2009;106:123-133. [PMID: 19568370 DOI: 10.3238/arztebl.2009.0123] [Cited by in Crossref: 11] [Cited by in F6Publishing: 26] [Article Influence: 0.8] [Reference Citation Analysis]
219 Tursi A, Elisei W, Picchio M, Giorgetti G, Brandimarte G. Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists. Dig Dis Sci 2015;60:1406-13. [PMID: 25445163 DOI: 10.1007/s10620-014-3459-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
220 Kornbluth A, Sachar DB;  Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501-23; quiz 524. [PMID: 20068560 DOI: 10.1038/ajg.2009.727] [Cited by in Crossref: 826] [Cited by in F6Publishing: 730] [Article Influence: 68.8] [Reference Citation Analysis]
221 Ferrante M, Karmiris K, Newnham E, Siffledeen J, Zelinkova Z, van Assche G, Lakatos PL, Panés J, Sturm A, Travis S, van der Woude CJ, Reinisch W, Colombel J, Panaccione R. Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: Results from an international survey and discussion programme. Journal of Crohn's and Colitis 2012;6:116-31. [DOI: 10.1016/j.crohns.2011.09.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
222 St. Charles M, Weiss Smith SR, Beardsley R, Fedder DO, Carter-pokras O, Cross RK. Gastroenterologistsʼ prescribing of infliximab for Crohnʼs disease: A national survey: . Inflammatory Bowel Diseases 2009;15:1467-75. [DOI: 10.1002/ibd.20904] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
223 Papi C, Festa V, Leandro G, Moretti A, Tanga M, Koch M, Capurso L. Long-Term Outcome of Crohn's Disease Following Corticosteroid-Induced Remission. Am J Gastroenterology 2007;102:814-9. [DOI: 10.1111/j.1572-0241.2007.01055.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
224 Mardini HE, Schwartz DA. Treatment of perianal fistula and abscess: Crohn’s and non-Crohn’s. Curr Treat Options Gastro 2007;10:211-20. [DOI: 10.1007/s11938-007-0014-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
225 Vaughn BP, Moss AC. Novel treatment options for ulcerative colitis. Clin Investig (Lond) 2013;3:1057-69. [PMID: 24533177 DOI: 10.4155/cli.13.97] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
226 Ha C, Dassopoulos T. Thiopurine therapy in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2010;4:575-588. [PMID: 20932143 DOI: 10.1586/egh.10.59] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
227 Jacob EM, Borah A, Pillai SC, Kumar DS. Inflammatory Bowel Disease: The Emergence of New Trends in Lifestyle and Nanomedicine as the Modern Tool for Pharmacotherapy. Nanomaterials (Basel) 2020;10:E2460. [PMID: 33316984 DOI: 10.3390/nano10122460] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
228 Chevaux J, Peyrin-biroulet L, Sparrow MP. Optimizing thiopurine therapy in inflammatory bowel disease: . Inflammatory Bowel Diseases 2011;17:1428-35. [DOI: 10.1002/ibd.21494] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
229 Pecher D, Dokupilová S, Zelinková Z, Peppelenbosch M, Mikušová V, Mikuš P. Determination of thiopurine S-methyltransferase activity by hydrophilic interaction liquid chromatography hyphenated with mass spectrometry. J Pharm Biomed Anal 2017;142:244-51. [PMID: 28525791 DOI: 10.1016/j.jpba.2017.05.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
230 Icht O, Yanai H, Ron Y, Rosner G, Yaron A, Waizbard A, Ziv-Baran T, Fishman S, Dotan I. Comparative Study of Two Cohorts of Newly Diagnosed Crohn's Disease Demonstrates Change in Therapeutic Strategies. Digestion 2017;96:135-41. [PMID: 28848118 DOI: 10.1159/000477438] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
231 Mahoro P, Moon HJ, Yang HJ, Kim KA, Cha YS. Protective Effect of Gochujang on Inflammation in a DSS-Induced Colitis Rat Model. Foods 2021;10:1072. [PMID: 34066160 DOI: 10.3390/foods10051072] [Reference Citation Analysis]
232 López San Román A, Rivero Fernández M. Estado actual del tratamiento de la enfermedad inflamatoria intestinal. Revista Clínica Española 2007;207:298-300. [DOI: 10.1157/13106853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
233 Engel MA, Neurath MF. New pathophysiological insights and modern treatment of IBD. J Gastroenterol. 2010;45:571-583. [PMID: 20213337 DOI: 10.1007/s00535-010-0219-3] [Cited by in Crossref: 116] [Cited by in F6Publishing: 118] [Article Influence: 9.7] [Reference Citation Analysis]
234 Cury DB, Cury MS, Elias GVH, Mizsputen SJ. Infliximab to treat severe ulcerative colitis. World J Gastroenterol 2009; 15(14): 1771-1773 [PMID: 19360923 DOI: 10.3748/wjg.15.1771] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
235 Montaner B, O'Donovan P, Reelfs O, Perrett CM, Zhang X, Xu YZ, Ren X, Macpherson P, Frith D, Karran P. Reactive oxygen-mediated damage to a human DNA replication and repair protein. EMBO Rep 2007;8:1074-9. [PMID: 17932513 DOI: 10.1038/sj.embor.7401084] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 4.5] [Reference Citation Analysis]
236 Absah I, Stephens M. Adjunctive treatment to antitumor necrosis factor in pediatric patient with refractory Crohn’s disease. Curr Opin Pediatr. 2013;Epub ahead of print. [PMID: 23995433 DOI: 10.1097/mop.0b013e328364df22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
237 Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B; Toronto Ulcerative Colitis Consensus Group. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148:1035-1058.e3. [PMID: 25747596 DOI: 10.1053/j.gastro.2015.03.001] [Cited by in Crossref: 211] [Cited by in F6Publishing: 180] [Article Influence: 30.1] [Reference Citation Analysis]
238 Tursi A, Elisei W, Picchio M, Penna A, Lecca PG, Forti G, Giorgetti G, Faggiani R, Zampaletta C, Pelecca G. Managing ambulatory ulcerative colitis patients with infliximab: a long term follow-up study in primary gastroenterology centers. Eur J Intern Med. 2014;25:757-761. [PMID: 25086677 DOI: 10.1016/j.ejim.2014.07.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
239 Danese S, Hart A, Dignass A, Louis E, D'Haens G, Dotan I, Rogler G, D'Agay L, Iannacone C, Peyrin-Biroulet L. Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study. BMJ Open Gastroenterol 2016;3:e000092. [PMID: 27239329 DOI: 10.1136/bmjgast-2016-000092] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
240 Zhang Z, Kennedy H. Ulcerative colitis: current medical therapy and strategies for improving medication adherence. Eur J Gastroenterol Hepatol. 2009;21:1-8. [PMID: 19011573 DOI: 10.1097/MEG.0b013e32830bfb88] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
241 Raine T. Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same? United European Gastroenterol J 2014;2:333-44. [PMID: 25360311 DOI: 10.1177/2050640614550672] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
242 Chiba M, Abe T, Tsuda H, Sugawara T, Tsuda S, Tozawa H, Fujiwara K, Imai H. Lifestyle-related disease in Crohn’s disease: Relapse prevention by a semi-vegetarian diet. World J Gastroenterol 2010; 16(20): 2484-2495 [PMID: 20503448 DOI: 10.3748/wjg.v16.i20.2484] [Cited by in CrossRef: 110] [Cited by in F6Publishing: 100] [Article Influence: 9.2] [Reference Citation Analysis]
243 Ham M, Moss AC. Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol 2012;5:113-23. [PMID: 22390554 DOI: 10.1586/ecp.12.2] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 6.7] [Reference Citation Analysis]
244 Newman WG, Payne K, Tricker K, Roberts SA, Fargher E, Pushpakom S, Alder JE, Sidgwick GP, Payne D, Elliott RA. A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. Pharmacogenomics. 2011;12:815-826. [PMID: 21692613 DOI: 10.2217/pgs.11.32] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 4.6] [Reference Citation Analysis]
245 Day MW. Fight back against inflammatory bowel disease. Nursing 2008;38:34-40. [DOI: 10.1097/01.nurse.0000341077.75953.74] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
246 Taha T, Meiri D, Talhamy S, Wollner M, Peer A, Bar-Sela G. Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies. Oncologist 2019;24:549-54. [PMID: 30670598 DOI: 10.1634/theoncologist.2018-0383] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 11.3] [Reference Citation Analysis]
247 Swaminath A, Ullman T, Rosen M, Mayer L, Lichtiger S, Abreu MT. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients. Aliment Pharmacol Ther. 2009;29:273-278. [PMID: 19006540 DOI: 10.1111/j.1365-2036.2008.03878.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
248 Zheng K, Shen H, Jia J, Lu Y, Zhu L, Zhang L, Shen Z. Traditional Chinese medicine combination therapy for patients with steroid-dependent ulcerative colitis: study protocol for a randomized controlled trial. Trials. 2017;18:8. [PMID: 28069051 DOI: 10.1186/s13063-016-1763-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
249 Nguyen ALH, Sparrow MP. Evolving Role of Thiopurines in Inflammatory Bowel Disease in the Era of Biologics and New Small Molecules. Dig Dis Sci 2021;66:3250-62. [PMID: 33073334 DOI: 10.1007/s10620-020-06662-z] [Reference Citation Analysis]
250 Serpe L, Canaparo R, Daperno M, Sostegni R, Martinasso G, Muntoni E, Ippolito L, Vivenza N, Pera A, Eandi M. Solid lipid nanoparticles as anti-inflammatory drug delivery system in a human inflammatory bowel disease whole-blood model. Eur J Pharm Sci. 2010;39:428-436. [PMID: 20138213 DOI: 10.1016/j.ejps.2010.01.013] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
251 Liu Y, Meng Y, Wang L, Liu Z, Li J, Dong W. Associations between the <i>NUDT15</i> R139C polymorphism and susceptibility to thiopurine-induced leukopenia in Asians: A meta-analysis. Onco Targets Ther. 2018;11:8309-8317. [PMID: 30538500 DOI: 10.2147/ott.s177007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
252 Sorrentino D. Role of biologics and other therapies in stricturing Crohn's disease: what have we learnt so far? Digestion. 2008;77:38-47. [PMID: 18285676 DOI: 10.1159/000117306] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
253 Zhang Y, Xia JJ, Xiao P, Zhao Y, Ye LN, Li XL, Lin ZW, Xu ZJ, Huang YB, Wang MY, Qian JM, Hu PJ, Cao Q. Standard-dose versus low-dose azathioprine in the treatment of Crohn's disease: A prospective randomized study: Azathioprine dose for CD. Journal of Digestive Diseases 2016;17:747-55. [DOI: 10.1111/1751-2980.12414] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
254 Lewis SN, Brannan L, Guri AJ, Lu P, Hontecillas R, Bassaganya-Riera J, Bevan DR. Dietary α-eleostearic acid ameliorates experimental inflammatory bowel disease in mice by activating peroxisome proliferator-activated receptor-γ. PLoS One 2011;6:e24031. [PMID: 21904603 DOI: 10.1371/journal.pone.0024031] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
255 Winter TA, Sandborn WJ, de Villiers WJ, Schreiber S. Treatment of Crohn’s disease with certolizumab pegol. Expert Review of Clinical Immunology 2014;3:683-94. [DOI: 10.1586/1744666x.3.5.683] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
256 Sherlock ME, MacDonald JK, Griffiths AM, Steinhart AH, Seow CH. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2015;26:CD007698. [PMID: 26497719 DOI: 10.1002/14651858.cd007698.pub3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
257 Byun JM, Lee CK, Rhee SY, Kim H, Im JP, Park DI, Eun CS, Jung S, Shin JE, Lee K, Cheon JH. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor. Scandinavian Journal of Gastroenterology 2014;50:312-20. [DOI: 10.3109/00365521.2014.1000960] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
258 Gisbert JP, Chaparro M, Gomollón F. Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease. World J Gastroenterol 2011; 17(30): 3467-3478 [PMID: 21941413 DOI: 10.3748/wjg.v17.i30.3467] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
259 Blonski W, Buchner AM, Lichtenstein GR. Clinical predictors of aggressive/disabling disease: ulcerative colitis and crohn disease. Gastroenterol Clin North Am. 2012;41:443-462. [PMID: 22500528 DOI: 10.1016/j.gtc.2012.01.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
260 Roblin X, Peyrin-Biroulet L, Phelip JM, Nancey S, Flourie B. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity. Am J Gastroenterol. 2008;103:3115-3122. [PMID: 19086961 DOI: 10.1111/j.1572-0241.2008.01743.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
261 Panaccione R, Steinhart AH, Bressler B, Khanna R, Marshall JK, Targownik L, Afif W, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C, Bernstein CN. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease. Clinical Gastroenterology and Hepatology 2019;17:1680-713. [DOI: 10.1016/j.cgh.2019.02.043] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
262 Rosenfeld G, Parker CE, MacDonald JK, Bressler B. Etrolizumab for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2015;:CD011661. [PMID: 26630451 DOI: 10.1002/14651858.CD011661.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
263 Irving PM, Gearry RB, Sparrow MP, Gibson PR. Review article: appropriate use of corticosteroids in Crohn's disease. Aliment Pharmacol Ther 2007;26:313-29. [PMID: 17635367 DOI: 10.1111/j.1365-2036.2007.03379.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
264 Dassopoulos T, Dubinsky MC, Bentsen JL, Martin CF, Galanko JA, Seidman EG, Sandler RS, Hanauer SB. Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. Aliment Pharmacol Ther. 2014;39:163-175. [PMID: 24237037 DOI: 10.1111/apt.12555] [Cited by in Crossref: 62] [Cited by in F6Publishing: 50] [Article Influence: 6.9] [Reference Citation Analysis]
265 Cross RK, Jambaulikar G, Langenberg P, Tracy JK, Collins JF, Katz J, Regueiro M, Schwartz DA, Quinn CC. TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD): Design and implementation of randomized clinical trial. Contemp Clin Trials 2015;42:132-44. [PMID: 25812483 DOI: 10.1016/j.cct.2015.03.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 6.1] [Reference Citation Analysis]
266 Vaughn BP, Shah S, Cheifetz AS. The role of mucosal healing in the treatment of patients with inflammatory bowel disease. Curr Treat Options Gastroenterol 2014;12:103-17. [PMID: 24395615 DOI: 10.1007/s11938-013-0008-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
267 Terao S, Yamashiro K, Tamura I, Hirano T, Ohkusa T, Kato K. Antibiotic Combination Therapy for Steroid Withdrawal in Steroid-Dependent Ulcerative Colitis. Digestion 2011;83:198-203. [DOI: 10.1159/000321811] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
268 Malgras B, Pautrat K, Dray X, Pasquier P, Valleur P, Pocard M, Soyer P. Multidisciplinary Management of Gastrointestinal Fibrotic Stenosis in Crohn’s Disease. Dig Dis Sci 2015;60:1152-68. [DOI: 10.1007/s10620-014-3421-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
269 Marchioni Beery R, Kane S. Current approaches to the management of new-onset ulcerative colitis. Clin Exp Gastroenterol. 2014;7:111-132. [PMID: 24872716 DOI: 10.2147/ceg.s35942] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
270 Smith MA, Irving PM, Marinaki AM, Sanderson JD. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther. 2010;32:119-130. [PMID: 20412066 DOI: 10.1111/j.1365-2036.2010.04330.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 5.4] [Reference Citation Analysis]
271 Gerich ME, Quiros JA, Marcin JP, Tennyson L, Henthorn M, Prindiville TP. A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine. Journal of Crohn's and Colitis 2010;4:546-52. [DOI: 10.1016/j.crohns.2010.03.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
272 Quaia E, Sozzi M, Angileri R, Gennari AG, Cova MA. Time-Intensity Curves Obtained after Microbubble Injection Can Be Used to Differentiate Responders from Nonresponders among Patients with Clinically Active Crohn Disease after 6 Weeks of Pharmacologic Treatment. Radiology 2016;281:606-16. [DOI: 10.1148/radiol.2016152461] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
273 Sandborn WJ, Travis S, Moro L, Jones R, Gautille T, Bagin R, Huang M, Yeung P, Ballard ED. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012;143:1218-1226.e1-2. [PMID: 22892337 DOI: 10.1053/j.gastro.2012.08.003] [Cited by in Crossref: 148] [Cited by in F6Publishing: 134] [Article Influence: 14.8] [Reference Citation Analysis]
274 Ooi CJ, Fock KM, Makharia GK, Goh KL, Ling KL, Hilmi I, Lim WC, Kelvin T, Gibson PR, Gearry RB. The Asia-Pacific consensus on ulcerative colitis. J Gastroenterol Hepatol. 2010;25:453-468. [PMID: 20370724 DOI: 10.1111/j.1440-1746.2010.06241.x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 99] [Article Influence: 8.1] [Reference Citation Analysis]
275 Yang L, Dou H, Song Y, Hou Y. Benzenediamine analog FC-99 inhibits TLR2 and TLR4 signaling in peritoneal macrophage in vitro. Life Sciences 2016;144:129-37. [DOI: 10.1016/j.lfs.2015.11.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
276 Lewis JD, Abramson O, Pascua M, Liu L, Asakura LM, Velayos FS, Hutfless SM, Alison JE, Herrinton LJ. Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations. Clin Gastroenterol Hepatol. 2009;7:1195-1201; quiz 1141-1142. [PMID: 19631285 DOI: 10.1016/j.cgh.2009.07.019] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
277 Choi CH, Moon W, Kim YS, Kim ES, Lee BI, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of ulcerative colitis. Intest Res. 2017;15:7-37. [PMID: 28239313 DOI: 10.5217/ir.2017.15.1.7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 7.4] [Reference Citation Analysis]
278 Shergill AK, Terdiman JP. Controversies in the treatment of Crohn’s disease: The case for an accelerated step-up treatment approach. World J Gastroenterol 2008; 14(17): 2670-2677 [PMID: 18461652 DOI: 10.3748/wjg.14.2670] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
279 Gao J, Jiang XL. Low-dose infliximab for corticosteroid-refractory ulcerative colitis: Impact of number of infusions on efficacy and safety. Shijie Huaren Xiaohua Zazhi 2013; 21(15): 1453-1457 [DOI: 10.11569/wcjd.v21.i15.1453] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
280 Tursi A, Elisei W, Picchio M, Penna A, Lecca PG, Forti G, Giorgetti G, Faggiani R, Zampaletta C, Pelecca G, Brandimarte G. Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres. European Journal of Internal Medicine 2014;25:485-90. [DOI: 10.1016/j.ejim.2014.02.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
281 Puthoor PR, de Zoeten EF. Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab. Biol Ther. 2013;3:1-14. [PMID: 24392300 DOI: 10.1007/s13554-012-0006-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
282 Hanauer S, Panaccione R, Danese S, Cheifetz A, Reinisch W, Higgins PDR, Woodworth DA, Zhang H, Friedman GS, Lawendy N, Quirk D, Nduaka CI, Su C. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019;17:139-147. [PMID: 30012431 DOI: 10.1016/j.cgh.2018.07.009] [Cited by in Crossref: 67] [Cited by in F6Publishing: 55] [Article Influence: 16.8] [Reference Citation Analysis]
283 Bermejo F, Gisbert JP. Usefulness of salicylate and thiopurine coprescription in steroid-dependent ulcerative colitis and withdrawal strategies. Ther Adv Chronic Dis 2010;1:107-14. [PMID: 23251733 DOI: 10.1177/2040622310374897] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
284 Choi CH, Moon W, Kim YS, Kim ES, Lee B, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Second Korean Guideline for the Management of Ulcerative Colitis. Korean J Gastroenterol 2017;69:1. [DOI: 10.4166/kjg.2017.69.1.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
285 Benchimol EI, Seow CH, Steinhart AH, Griffiths AM. Traditional corticosteroids for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008;CD006792. [PMID: 18425970 DOI: 10.1002/14651858.cd006792.pub2] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
286 Panaccione R, Fedorak RN, Aumais G, Bernard EJ, Bernstein CN, Bitton A, Croitoru K, Dieleman LA, Enns R, Feagan BG, Franchimont D, Greenberg GR, Griffiths AM, Marshall JK, Pare P, Patel S, Penner R, Render C, Seidman E, Steinhart AH. Review and clinical perspectives for the use of infliximab in ulcerative colitis. Can J Gastroenterol 2008;22:261-72. [PMID: 18354755 DOI: 10.1155/2008/493405] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
287 Grossman AB, Baldassano RN. Specific considerations in the treatment of pediatric inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2008;2:105-124. [PMID: 19072374 DOI: 10.1586/17474124.2.1.105] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
288 Decara J, Rivera P, López-Gambero AJ, Serrano A, Pavón FJ, Baixeras E, Rodríguez de Fonseca F, Suárez J. Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases. Front Pharmacol 2020;11:730. [PMID: 32536865 DOI: 10.3389/fphar.2020.00730] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
289 Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007;:CD000478. [PMID: 17253451 DOI: 10.1002/14651858.CD000478.pub2] [Cited by in Crossref: 63] [Cited by in F6Publishing: 33] [Article Influence: 4.2] [Reference Citation Analysis]
290 Tursi A, Mocci G, Faggiani R, Allegretta L, Valle ND, Forti G, Franceschi M, Ferronato A, Gallina S, Larussa T, Luzza F, Lorenzetti R, Penna A, Rodino S, Sebkova L, Lauria A, Piergallini S, Pranzo G, Ricciardelli C, Zampaletta C, Elisei W, Picchio M. Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers. Ann Gastroenterol 2019;32:392-9. [PMID: 31263362 DOI: 10.20524/aog.2019.0377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
291 Pastorelli L, Pizarro TT, Cominelli F, Vecchi M. Emerging drugs for the treatment of ulcerative colitis. Expert Opin Emerg Drugs 2009;14:505-21. [PMID: 19656075 DOI: 10.1517/14728210903146882] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
292 Taylor KM, Irving PM. Optimization of conventional therapy in patients with IBD. Nat Rev Gastroenterol Hepatol. 2011;8:646-656. [PMID: 21970871 DOI: 10.1038/nrgastro.2011.172] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 3.6] [Reference Citation Analysis]
293 Baumgart DC, Macdonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev. 2008;CD007216. [PMID: 18646177 DOI: 10.1002/14651858.cd007216] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
294 Abraham NS, Richardson P, Castillo D, Kane SV. Dual Therapy With Infliximab and Immunomodulator Reduces One-Year Rates of Hospitalization and Surgery Among Veterans With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 2013;11:1281-7. [DOI: 10.1016/j.cgh.2013.06.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
295 Park SH, Yang SK, Park SK, Kim JW, Yang DH, Jung KW, Kim KJ, Ye BD, Byeon JS, Myung SJ, Kim JH. Efficacy of hepatitis A vaccination and factors impacting on seroconversion in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:69-74. [PMID: 24284413 DOI: 10.1097/01.mib.0000437736.91712.a1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
296 Ramakrishna BS, Makharia GK, Abraham P, Ghoshal UC, Jayanthi V, Agarwal BK, Ahuja V, Bhasin DK, Bhatia SJ, Choudhuri G. Indian Society of Gastroenterology consensus on ulcerative colitis. Indian J Gastroenterol. 2012;31:307-323. [PMID: 23096266 DOI: 10.1007/s12664-012-0259-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
297 Gisbert JP, Gomollón F. Errores frecuentes en el manejo del paciente ambulatorio con enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2007;30:469-86. [DOI: 10.1157/13110491] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
298 Majumder K, Fukuda T, Zhang H, Sakurai T, Taniguchi Y, Watanabe H, Mitsuzumi H, Matsui T, Mine Y. Intervention of Isomaltodextrin Mitigates Intestinal Inflammation in a Dextran Sodium Sulfate-Induced Mouse Model of Colitis via Inhibition of Toll-like Receptor-4. J Agric Food Chem 2017;65:810-7. [PMID: 28102669 DOI: 10.1021/acs.jafc.6b04903] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
299 Swoger JM, Loftus EV, Tremaine WJ, Faubion WA, Pardi DS, Kane SV, Hanson KA, Harmsen WS, Zinsmeister AR, Sandborn WJ. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis. 2010;16:1912-1921. [PMID: 20848486 DOI: 10.1002/ibd.21272] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 3.5] [Reference Citation Analysis]
300 Tursi A, Mocci G, Faggiani R, Allegretta L, Valle ND, Medici A, Forti G, Franceschi M, Ferronato A, Gallina S, Grasso G, Larussa T, Luzza F, Lorenzetti R, Penna A, Rodino' S, Sebkova L, Lauria A, Piergallini S, Pranzo G, Scorza S, Zampaletta C, Picchio M, Elisei W. Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers. Eur J Intern Med 2019;66:85-91. [PMID: 31208827 DOI: 10.1016/j.ejim.2019.06.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
301 Regueiro MD, Greer JB, Hanauer SB. Established Management Paradigms in IBD: Treatment Targets and Therapeutic Tools. Am J Gastroenterol Suppl 2016;3:8-16. [DOI: 10.1038/ajgsup.2016.16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
302 Bujňáková D, Juhás Š, Faix Š. The anti-translocation and anti-inflammatory effect of cinnamon oil in mice with TNBS induced colitis. Biologia 2013;68:1000-3. [DOI: 10.2478/s11756-013-0231-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
303 Yip JS, Woodward M, Abreu MT, Sparrow MP. How are Azathioprine and 6-mercaptopurine dosed by gastroenterologists? Inflamm Bowel Dis. 2008;14:514-518. [PMID: 18088072 DOI: 10.1002/ibd.20345] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
304 Stoppino LP, Della Valle N, Rizzi S, Cleopazzo E, Centola A, Iamele D, Bristogiannis C, Stoppino G, Vinci R, Macarini L. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers. BMC Med Imaging 2016;16:37. [PMID: 27149857 DOI: 10.1186/s12880-016-0139-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
305 Gionchetti P, Rizzello F, Annese V, Armuzzi A, Biancone L, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D'Incà R, Fries W, Kohn A, Orlando A, Papi C, Vecchi M, Ardizzone S; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease.Dig Liver Dis. 2017;49:604-617. [PMID: 28254463 DOI: 10.1016/j.dld.2017.01.161] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
306 Wright EK, Ding NS, Niewiadomski O. Management of inflammatory bowel disease. Med J Aust 2018;209:318-23. [PMID: 30257634 DOI: 10.5694/mja17.01001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
307 Ren K, Yuan H, Zhang Y, Wei X, Wang D. Macromolecular glucocorticoid prodrug improves the treatment of dextran sulfate sodium-induced mice ulcerative colitis. Clin Immunol 2015;160:71-81. [PMID: 25869296 DOI: 10.1016/j.clim.2015.03.027] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]